PAHC

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 52,200

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.14 to $57.24.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 52,480

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.12 to $57.06.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 59,240

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.76 to $56.91.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 59,792

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.76 to $56.745.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 64,708

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.69 to $55.65.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,280

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $53.70.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-035447 · tm269871-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,797

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.44 to $53.435. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 9.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,320

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,444

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.195 to $53.125.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 78,421

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.19 to $52.18.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 80,360

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.365 to $53.88.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 83,011

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.35 to $53.295.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 86,609

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.29 to $52.21.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-032252 · tm269323-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 90,920

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on December 11, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.26 to $52.13. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 8.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 96,200

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on December 11, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.48 to $49.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · derivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,596,034

Underlying: Class A Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-028472 · tm268840-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 101,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 1,480

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.27 to $54.355.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 2,191

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.21 to $54.10.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 8,520

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.275 to $52.27.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 15,560

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.80 to $52.065.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-020787 · tm267373-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 16,711

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.755 to $51.75. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 through 7.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 22,600

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.92 to $52.06.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 22,997

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.89.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-018606 · tm266984-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 29,640

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.965 to $50.935. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 36,680

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.90 to $52.05.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 36,896

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.90 to $51.875.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-017198 · tm266654-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 43,720

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.61 to $52.345. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 50,760

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.205 to $52.21.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 50,994

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.11 to $52.04.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-013378 · tm265965-2_4seq1.xml · nonDerivative · entry 2

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,317

F2 · shares: Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 64,944

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.10 to $52.30.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-013602 · tm265965-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 71,964

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.10 to $52.09. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5 and 6.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-013378 · tm265965-2_4seq1.xml · derivative · entry 3

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,000

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.

F4 · derivative.exercise_date: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F5 · derivative.exercise_date: Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

F4 · derivative.expiration_date: On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

F5 · derivative.expiration_date: Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.

SEC source: 0001104659-26-013378 · tm265965-2_4seq1.xml · nonDerivative · entry 1

David Glenn · CIK 0001606256 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · derivative · entry 9

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,696,034

Underlying: Class A Common Stock · 185,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 122,958

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.18 to $50.01.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 142,096

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.175 to $49.17.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 188,371

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.17 to $48.17.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 226,580

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.10 to $47.08.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 229,751

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.04 to $46.02.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 233,391

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.035 to $44.73. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 through 9.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-012073 · tm265586-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 233,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,881,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F5 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 48,800

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.535 to $41.52.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 52,320

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 22,320

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.70 to $42.62.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-011113 · tm265335-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 25,291

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.69 to $41.68. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 6.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-009210 · tm264637-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,980

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.365.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-26-009210 · tm264637-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,673

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.475. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.